Cryoablation of cancer in the prostate will employ technology provided by Endocare, Irvine, California. Virgin dendritic cells (VDC2008) consist of each patient’s own immature dendritic cells obtained from blood-borne precursors and introduced back to the individual.
Dendritic cells are said to be capable of triggering a highly specific immune response against antigenic targets systemically. According to the company, cryoablation of cancer releases numerous antigens, and intratumoral injection of VDC2008 into this antigen-rich environment may result in targeted immune-mediated destruction of cancer metastases.
Duke Bahn, investigator of the study, said: “Through the application of VDC2008, we will attempt to leverage this potential by combining cancer ablation with immune-activating therapy.”